Boundless Bio, Inc.
Boundless Bio, Inc. (BOLD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bold · stock forecast · 20 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 20 Wall Street analysts in the past 3 months
Hold
20 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.43
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.41 | ↓ 1.53% |
1-day model range: $1.4–$1.42. Peak: $1.42 (-1.53%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BOLD · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-08-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-28 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2024-12-13 | Guggenheim | Downgrade ↓ | Buy→Neutral |
| 2019-12-08 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2019-12-05 | JP Morgan | Downgrade ↓ | Overweight→Neutral |
| 2019-12-04 | SVB Leerink | Downgrade ↓ | Outperform→Perform |
| 2019-12-03 | SVB Leerink | Downgrade ↓ | Outperform→Market Perform |
| 2019-12-03 | Chardan Capital | Downgrade ↓ | Buy→Neutral |
| 2019-12-03 | Raymond James | Downgrade ↓ | Outperform→Perform |
| 2019-12-03 | BMO Capital | Downgrade ↓ | Outperform→Perform |
Wall Street analysts have recently issued updated ratings on Boundless Bio, Inc. (BOLD) stock. Of the recent 43 rating actions, 6 were upgrades and 18 were downgrades. 20 analysts currently cover BOLD.
Analyst Recommendation Trends
BOLD analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-2.38
EPS Next Year
$-1.28
↓ 46.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast BOLD EPS of $-2.38 for the current fiscal year, based on estimates from 2 analysts. The BOLD revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BOLD stock forecast is supported by two independent data sources: analyst consensus ratings from 20 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BOLD price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The BOLD short-term stock prediction for tomorrow is $1.41 (-1.53%). The BOLD stock price prediction for 2027 estimates an average of $1. The BOLD stock prediction for 2030 projects a range of $0–$0.
Boundless Bio, Inc. trades on NASDAQ under the ticker BOLD. The BOLD stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 30% of covering analysts.
Frequently asked questions
BOLD forecast · 8 questionsAccording to 20 Wall Street analysts, the average 12-month BOLD price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.43.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.